JP Morgan Reinstates Neutral on Cerevel Therapeutics Hldg, Announces $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye has reinstated coverage on Cerevel Therapeutics Holdings (CERE) with a Neutral rating and set a price target of $25.

November 20, 2023 | 12:44 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan analyst Jessica Fye reinstated Cerevel Therapeutics Holdings with a Neutral rating and a price target of $25.
The reinstatement of coverage by JP Morgan with a Neutral rating and a specific price target provides investors with a professional analysis of CERE's value. However, a Neutral rating suggests that the analyst sees the stock as fairly valued at its current price, implying no significant short-term price movement is expected unless new, more impactful information becomes available.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100